Content about Recombinant proteins

April 5, 2013
Novo Nordisk launches Race with Insulin contest with Charlie Kimball as spokesman

Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said.

February 19, 2013
Mylan, Biocon enter deal on generic analog insulins

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

February 11, 2013
FDA turns down two Novo Nordisk insulin products

The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

November 28, 2012
Novo Nordisk app designed to help hemophilia patients, families

Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

November 9, 2012
FDA panel recommends approval for two Novo Nordisk insulin products

A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

June 12, 2012
Global study reveals correlation between insulin dosing irregularities, hypoglycemia

One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.

June 11, 2012
Study: Insulin degludec reduces risk of nocturnal hypoglycemia among Type 2 diabetes patients

An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.

May 22, 2012
BD introduces syringe with smaller needle for diabetes patients

Medical supply manufacturer BD has released a syringe with a shorter needle designed to reduce discomfort in patients with diabetes who must inject insulin, the company said Tuesday.

April 2, 2012
FDA OKs Levemir for pregnant women

A diabetes treatment made by Novo Nordisk is safe for pregnant women, according to a recent decision by the Food and Drug Administration.

March 13, 2012
Pfizer, Biocon end biosimilar insulin deal

Pfizer and Indian drug maker Biocon have ended a partnership that the companies started in 2010 to develop biosimilar treatments for diabetes, the companies said.

January 30, 2012
Actavis partners with Poland's Bioton to develop insulin products

Iceland-based drug maker Actavis and Poland-based Bioton have formed a partnership that they said would "shake up" the diabetes market.

January 16, 2012
FDA issues alert about sharing of insulin pens

The Food and Drug Administration's latest message to consumers and healthcare professionals seems like a no-brainer: "Insulin pens are not for sharing."

December 8, 2011
Insulin combination treats low blood sugar in diabetes patients, study finds

A combination of two insulins made by Novo Nordisk reduced abnormally low blood sugar in diabetes patients, according to study results presented at a medical conference.

October 20, 2011
Byetta approved for use with Lantus

A diabetes drug made by Eli Lilly and Amylin Pharmaceuticals has received approval from the Food and Drug Administration for use with an insulin product made by Sanofi.

September 30, 2011
Novo Nordisk seeks to market insulin products

Novo Nordisk is seeking approval for two new insulin products, the company said Thursday.

September 13, 2011
Study: Sanofi insulin reduces weight gain, increases blood sugar control

An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

July 6, 2011
MannKind: Patients have better view of insulin therapy when using Afrezza

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

June 28, 2011
Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions

A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.

June 27, 2011
Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment

An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 9, 2011
FDA approves labeling change for Eli Lilly insulin product

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

June 2, 2011
Insulet acquires Neighborhood Diabetes

A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

May 31, 2011
Sanofi: Lyxumia won't significantly increase hypoglycemia risk

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

March 24, 2011
Novo Nordisk says Levemir is effective in treating young Type 1 diabetes patients

Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

March 14, 2011
Biodel discloses accelerated development plan for diabetes drugs

A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

© 2013 Drug Store News. All Rights Reserved.